GEG Tech
GEG Tech is a biotechnology company founded in 2013 in Paris, France, specializing in genetic engineering and innovative platforms for gene therapy, immunotherapy, and vaccination. The company invests in R&D, partners with academic and industrial groups, and develops advanced genetic tools and vectors for therapeutic applications. Their mission is to design safe and powerful innovations in genetic engineering, with a focus on cancer immunotherapy, mRNA vaccination, and gene therapy applications.
Industries
Nr. of Employees
small (1-50)
GEG Tech
Products
DNA vector systems (integrating & non‑integrating)
Platform offerings of DNA-based vectors for research and therapeutic applications in both integrating and non-integrating formats.
mRNA vector systems
Proprietary mRNA vector platform intended for applications such as editing delivery and nucleic-acid vaccination.
Protein vector systems (VLPs)
Protein-based delivery vectors such as virus‑like particles for cargo delivery.
DNA vector systems (integrating & non‑integrating)
Platform offerings of DNA-based vectors for research and therapeutic applications in both integrating and non-integrating formats.
mRNA vector systems
Proprietary mRNA vector platform intended for applications such as editing delivery and nucleic-acid vaccination.
Protein vector systems (VLPs)
Protein-based delivery vectors such as virus‑like particles for cargo delivery.
Services
End-to-end design and production of custom DNA, RNA and protein-based vectors for research and preclinical applications.
Off-the-shelf lentiviral vectors provided for research use to accelerate R&D workflows.
Generation of bespoke standard and complex cell lines tailored to experimental requirements.
Design and production of genetically defined animal models for in vivo studies.
Production services for standard and complex recombinant proteins for research and preclinical use.
Co-development programs and research collaborations with academic and industrial partners leveraging internal vector platforms.
End-to-end design and production of custom DNA, RNA and protein-based vectors for research and preclinical applications.
Off-the-shelf lentiviral vectors provided for research use to accelerate R&D workflows.
Generation of bespoke standard and complex cell lines tailored to experimental requirements.
Design and production of genetically defined animal models for in vivo studies.
Production services for standard and complex recombinant proteins for research and preclinical use.
Co-development programs and research collaborations with academic and industrial partners leveraging internal vector platforms.
Expertise Areas
- Viral vector design and manufacturing
- mRNA therapeutic and vaccine development
- Genome editing vectorization (CRISPR/prime/base editing)
- CAR‑T and cancer immunotherapy enablement
Key Technologies
- Lentiviral vectors
- DNA integrating and non‑integrating vector systems
- mRNA vector platforms
- Virus‑like particle (VLP) vectors
News & Updates
Press Release January 20th, 2025 Retinal gene therapy: Visual cycle restored in blind mice.
GEG Tech launches a series of collaborations with leading research.
La Tribune highlights our biotech company GEG-Tech, whose research laboratory.
Press Release January 20th, 2025 Retinal gene therapy: Visual cycle restored in blind mice.
Press Release January 20th, 2025 Retinal gene therapy: Visual cycle restored in blind mice.
GEG Tech launches a series of collaborations with leading research.
La Tribune highlights our biotech company GEG-Tech, whose research laboratory.
Press Release January 20th, 2025 Retinal gene therapy: Visual cycle restored in blind mice.